Category: US

NIH to Launch Massive ACTIV-6 Phase 3 Clinical Study Investigating Repurposed Drugs & Ivermectin May be on the List

NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.

Read More »

Doctor’s Advice on Early Treatment for COVID-19

Every viral illness starts that way. The more it’s allowed to progress, the more it takes over the cells and replicates itself. That’s why this virus absolutely had to be treated early to prevent those damages. Primarily what has killed people with COVID is a delay to treatment, and allowing the exaggerating inflammatory response and blood clotting response to take hold in the body.

Read More »

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

Front Line COVID-19 Critical Care Alliance Statement – Weak Guidance on Ivermectin from the World Health Organization (WHO)

“I am deeply troubled that the WHO made this hasty decision on guidance before reviewing all available data,” said Pierre Kory, MD, MPH, president and chief medical officer of the FLCCC.
“Their recommendation ignores the evidence, creates more controversy, and will only lead to continuing suffering and death from COVID-19. There are now over 24 randomized trials results
that have been reported to the Unitaid/WHO team yet todays guidance was inexcusably based on a faulty analysis of just 16 of the available trials. Further, these erroneous findings directly conflict
with numerous other peer-reviewed expert analyses that have found the data overwhelmingly demonstrates that ivermectin saves lives from COVID-19. There is no reason not to recommend it
for everyone as a safe drug for prevention and treatment.”

Read More »

Timing and dosing are the key to HCQ + AZ treatment in elderly Covid-19 patients

Antiviral therapy is only of interest during the early and intermediate viral phase when the virus is present and replicates, and is of no use during the late inflammatory phase (cytokine storm). Most therapeutic trials, unfortunately, have been carried out in hospitalized patients, which is to say probably often too late, because the patients are in the early inflammatory phase.

Read More »

Ivermectin: How a nurse saved herself from her battle with COVID-19

The doctor refused and put her on other medicines. Patti’s condition deteriorated further, and when she returned a second time to the ER, she was again refused ivermectin and sent home on oxygen. When her condition failed to improve over several weeks, she finally obtained a prescription for ivermectin from a doctor and within days, she began to recover.

Read More »

Censorship Kills: The Shunning of a COVID Therapeutic

The science shows that ivermectin works. Over 40 randomized trials and observational studies from around the world attest to its efficacy against the novel coronavirus. Meta-analyses by four separate research groups, including ours, found an average reduction in mortality of between 68%-75%. And 10 of 13 randomized controlled trials found statistically significant reductions in time to viral clearance, an effect not associated with any other COVID-19 therapeutic. Furthermore, ivermectin has an unparalleled safety record and low cost, which should negate any fears or resistance to immediate adoption.

Read More »

Professor Risch Responds to Dr Rushworth over Hydroxychloroquine Post

“As a clinician, you should know that Covid-19 outpatient disease is viral replication, vs hospitalized disease which is florid pneumonia. These are absolutely different conditions and studies of the treatment of one cannot be extrapolated to the treatment of the other.
This massive body of evidence, summarized by the Cochrane Library, demonstrates that well-conducted hydroxychloroquine observational studies on average, produce very similar associations as the corresponding RCTs.

Read More »

The Chloroquine Wars Part II

On face, it certainly appears that complete silence in the public sphere about hydroxychloroquine’s potential was coordinated by powerful media forces.

Read More »

UK: Lice and scabies drug, Ivermectin, could cut Covid deaths by up to 75%, research suggests

More than 30 trials across the world found that ivermectin causes ‘repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease. The peer-reviewed study, to be published in the US journal Frontiers of Pharmacology, says the evidence is so strong that the drug – used to treat head lice and scabies – should become a standard therapy everywhere, so hastening the global recovery.

Read More »

Killing the cure: The strange war against hydroxychloroquine

The UK has had the ignominious triumph of having one of the world’s highest death rates. Some see the solution in continuing lockdowns, more testing and ultimately the vaccine. We argue that the solution lies in medical treatments, such as hydroxychloroquine or ivermectin rather than in vaccination. But hydroxychloroquine was ruled out as a potential treatment for covid19 quite early on. This is despite the fact that, when used correctly, it is a highly efficacious treatment. Had it been readily available as a prophylactic or early stage treatment we would need neither lockdowns nor vaccinations and dramatically fewer people would have died. However this didn’t happen. Here we intend to explore why.

Read More »